KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Equity Average (2018 - 2025)

Historic Equity Average for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Q3 2025 value amounting to -$111.2 million.

  • Amneal Pharmaceuticals' Equity Average fell 4728.84% to -$111.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$111.2 million, marking a year-over-year decrease of 4728.84%. This contributed to the annual value of -$44.8 million for FY2024, which is 14387.52% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Equity Average of -$111.2 million as of Q3 2025, which was down 4728.84% from -$122.3 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Equity Average registered a high of $387.2 million during Q1 2022, and its lowest value of -$122.3 million during Q2 2025.
  • Moreover, its 5-year median value for Equity Average was $152.5 million (2023), whereas its average is $130.2 million.
  • Its Equity Average has fluctuated over the past 5 years, first soared by 881.63% in 2022, then plummeted by 45369.8% in 2025.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Equity Average stood at $375.1 million in 2021, then plummeted by 49.57% to $189.1 million in 2022, then plummeted by 53.94% to $87.1 million in 2023, then tumbled by 216.55% to -$101.5 million in 2024, then decreased by 9.56% to -$111.2 million in 2025.
  • Its Equity Average stands at -$111.2 million for Q3 2025, versus -$122.3 million for Q2 2025 and -$120.8 million for Q1 2025.